Every day lost by sites is a day lost to the study sponsor and a day lost to the patients. Every dollar lost by sites is a dollar lost to the study sponsor and ten dollars lost to the patients.
The Site Council is an industry collaboration that speaks with a common voice to eradicate serious problems that sites have had with sponsors and CROs and the converse for over 40 years. By sapping time, money and energy, these problems interfere with effective study conduct. We have discussed these problems and possible solutions in countless forums, but we have systemically solved only one of them: redundant GCP training for principal investigators. Talk therapy isn't working.
It doesn't have to be this way. Let's try a new, collaborative approach to solving these problems. The patients can’t wait.
COMING SOON: The Site Council Directory of Key Performance Leaders (KPLs) will be provided free of charge to study sponsors and CROs who want expert site perspectives on the practical aspects of clinical study design and conduct. Without such expertise, study sponsors and CROs often make serious errors in study design, protocol complexity, eligibility criteria, site selection strategy, technology selection, patient recruitment strategies, etc. Key Opinion Leaders (KOLs) play a vital role in clinical research, but they are not usually experts in the practical aspects. Sites with KPLs also tend to be high performers. To learn more, contact us at support@sitecouncil.org.
The Site Council is growing fast, with over 3,000 site members. No membership fees, no paperwork, no demands, no deadlines, just gentle encouragement of study sponsors and CROs.
To view the Executive Committee, click here. To join the Site Council, click here.
The clinical research enterprise can succeed only when study sponsors and CROs have healthy relationships with healthy sites – that is our Dream. It may not be sustainable otherwise.
The Site Council Dream clarifies site priorities for sponsors and CROs. Member sites gently encourage sponsors and CROs to support the Site Council Dream. No membership fees, no paperwork, just communication. To benefit from the Site Council Dream, sites must conduct clinical studies in a safe, ethical, efficient, high-quality and timely manner.
The Site Council is addressing fundamental problems that needlessly inflate costs, timelines and risks in the clinical research enterprise. Let’s stop bailing and start fixing the boat.
The Site Council Dream lists 25 serious problems in six areas:
To view the Site Council Dream, click here.
Sponsors and CROs support the Site Council Dream by working constructively to implement it over time. The magic happens when sponsors and CROs realize that their support is to their benefit because (a) the Site Council Dream is their checklist for becoming a study sponsor or CRO of choice and (b) resolving these problems will free up site resources to conduct their clinical research studies better.
To view Supporters, click here.
The consensus opinion of senior clinical operations executives is that over half – yes, half – of the cost and time in a typical clinical trial is wasted. Some say 80%. Do the math on your own studies: Compare the cost of the test article, procedures, tests, and assessments that generate data to the total cost of the study – it will probably be a tiny fraction, perhaps only one percent of total study costs. Do sites really need study coordinators spending one day a week on redundant data entry? Armies of CTA negotiators renegotiating the same terms over and over again? Legions of accounts-receivable clerks chasing late and poorly documented payments from study sponsors and CROs?
The deceptively named Inflation Reduction Act of 2022 includes one section that, while misguided and perhaps even counterproductive, may reduce inflation: the prescription drug provisions. These provisions direct Medicare to "negotiate" drug prices with pharmaceutical companies. To read Wall St. Journal editorial, click here.
The Supreme Court will probably have something to say about the coercive overreach of these provisions, but the larger issue is that there is bipartisan support for government intervention in drug pricing. The harsh reality is that the high cost of many essential drugs is simply not sustainable. We can talk about the high value of high-priced drugs, but Medicare’s pockets – and the pockets of our health system, in general – are just not deep enough to cover their costs when widely prescribed.
